tiprankstipranks
Advertisement
Advertisement

NWPHF Stock Latest News

Newron Pharmaceuticals’ Earnings Call Signals Pivotal Year Ahead
Company AnnouncementsNewron Pharmaceuticals’ Earnings Call Signals Pivotal Year Ahead
14d ago
Newron Pharma price target raised to CHF 48 from CHF 43 at H.C. Wainwright
PremiumThe Fly
Newron Pharma price target raised to CHF 48 from CHF 43 at H.C. Wainwright
15d ago
Newron bolsters finances as Evenamide enters pivotal global Phase III
PremiumCompany Announcements
Newron bolsters finances as Evenamide enters pivotal global Phase III
17d ago
Newron Fortifies Evenamide Phase III Push with Fresh Capital, Patent Win and Board Overhaul
PremiumCompany Announcements
Newron Fortifies Evenamide Phase III Push with Fresh Capital, Patent Win and Board Overhaul
17d ago
Newron to Highlight Phase III Evenamide Data at 2026 Schizophrenia Congress
PremiumCompany Announcements
Newron to Highlight Phase III Evenamide Data at 2026 Schizophrenia Congress
21d ago
Newron extends EIB loan maturities to align financing with Evenamide milestones
PremiumCompany AnnouncementsNewron extends EIB loan maturities to align financing with Evenamide milestones
22d ago
Newron refreshes board with CNS and capital markets experts ahead of AGM
Premium
Company Announcements
Newron refreshes board with CNS and capital markets experts ahead of AGM
23d ago
Newron Raises Up to EUR 38 Million to Advance Phase III Schizophrenia Drug Evenamide
Premium
Company Announcements
Newron Raises Up to EUR 38 Million to Advance Phase III Schizophrenia Drug Evenamide
2M ago
Newron Raises Up to EUR 38 Million to Advance Phase III Schizophrenia Drug
PremiumCompany Announcements
Newron Raises Up to EUR 38 Million to Advance Phase III Schizophrenia Drug
2M ago
Newron’s Evenamide Shows Durable Benefits as Add-On Therapy in Treatment-Resistant Schizophrenia
PremiumCompany Announcements
Newron’s Evenamide Shows Durable Benefits as Add-On Therapy in Treatment-Resistant Schizophrenia
2M ago
Newron Pharma price target raised to CHF 43 from CHF 26 at H.C. Wainwright
PremiumThe Fly
Newron Pharma price target raised to CHF 43 from CHF 26 at H.C. Wainwright
3M ago
PremiumCompany Announcements
EA Pharma Starts Phase III Trial of Newron’s Evenamide for Treatment‑Resistant Schizophrenia in Japan
3M ago
PremiumCompany AnnouncementsNewron Secures EU Patent Extension for Lead Schizophrenia Drug Evenamide
3M ago
Premium
Company Announcements
Newron Wins Long-Term EU Patent Protection for Lead Schizophrenia Drug Evenamide
3M ago
Newron Pharma initiated with a Buy at Lucid Capital
Premium
The Fly
Newron Pharma initiated with a Buy at Lucid Capital
4M ago
Newron Pharmaceuticals’ Evenamide Advances with ENIGMA-TRS 2 Trial: Analyst Reiterates Buy Rating
PremiumRatings
Newron Pharmaceuticals’ Evenamide Advances with ENIGMA-TRS 2 Trial: Analyst Reiterates Buy Rating
4M ago
Newron Pharma initiated with a Buy at H.C. Wainwright
PremiumThe Fly
Newron Pharma initiated with a Buy at H.C. Wainwright
4M ago
Newron Pharmaceuticals Launches Phase III Study for Schizophrenia Treatment
PremiumCompany Announcements
Newron Pharmaceuticals Launches Phase III Study for Schizophrenia Treatment
4M ago
Newron Pharmaceuticals’ Phase III Study on Evenamide: A Potential Game-Changer for Treatment-Resistant Schizophrenia
PremiumCompany Announcements
Newron Pharmaceuticals’ Phase III Study on Evenamide: A Potential Game-Changer for Treatment-Resistant Schizophrenia
5M ago
NWPHF
Newron Pharmaceuticals Advances Evenamide for Schizophrenia Treatment
PremiumCompany AnnouncementsNewron Pharmaceuticals Advances Evenamide for Schizophrenia Treatment
6M ago
Newron Pharmaceuticals Advances Evenamide Development with Positive H1 2025 Results
Premium
Company Announcements
Newron Pharmaceuticals Advances Evenamide Development with Positive H1 2025 Results
7M ago
Newron Pharmaceuticals Advances Evenamide Phase III Trials for Schizophrenia
Premium
Company Announcements
Newron Pharmaceuticals Advances Evenamide Phase III Trials for Schizophrenia
7M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >